Dale Kostman Joins Angstrom Pharmaceuticals as Chief Financial Officer.SAN DIEGO--(BW HealthWire)--May 3, 1999-- Angstrom angstrom (ăng`strəm), abbr. Å, unit of length equal to 10−10 meter (0.0000000001 meter); it is used to measure the wavelengths of visible light and of other forms of electromagnetic radiation, such as ultraviolet Pharmaceuticals Inc. today announced that Dale J. Kostman has joined the company as their chief financial officer. Kostman will be responsible for the overall financial management of the company, including short-term capital formation, strategic planning, establishment of financial policies, historical accounting, and administrative functions. He will report to Terence R. Jones, Ph.D., chairman and chief executive officer. "Dale's extensive background and proven abilities in the financial management of diversified operations will be of immediate and long-term benefit as Angstrom continues to fulfill its key growth strategies," Jones said. "We are pleased to welcome him to our management team." Kostman possesses over 27 years of broad business experience with special competence in managing the financial growth and well being of entrepreneurial and middle market companies. He has a strong background in financial reporting, budgeting, and strategic planning, along with MIS, manufacturing and human resources administration. Kostman began his career as a cost accountant for Hewlett Packard in San Diego. He went on to hold Corporate Controller, Director of Finance, CFO See Chief Financial Officer. and CFO/COO posts in a number of companies as he developed his career. As CFO, he directed the successful IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. of one of these, WIZ Technology Inc., on the American Stock Exchange American Stock Exchange (AMEX) Stock exchange in the U.S. Originally known as “the Curb,” it began as an outdoor marketplace in New York City c. 1850. It moved indoors to its present location in the Wall Street area in 1921. . Kostman holds a B.S. in Accounting from San Diego State University San Diego State University (SDSU), founded in 1897 as San Diego Normal School, is the largest and oldest higher education facility in the greater San Diego area (generally the City and County of San Diego), and is part of the California State University system. and has done graduate work in psychology at the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. . Angstrom Pharmaceuticals (www.angstrominc.com) was formed in 1996 to add a new dimension to drug discovery. The company is committed to discovering small-molecule drugs that "switch off" extracellular cytokine-receptor interactions responsible for initiating disease processes. The company has chosen cancer as its first focus and is currently outlicensing its proprietary non-toxic, anti-angiogenic drugs that target urokinase urokinase /uro·ki·nase/ (UK) (u?ro-ki´nas) u-plasminogen activator; an enzyme in the urine of humans and other mammals, elaborated by the parenchymal cells of the human kidney and acting as a plasminogen activator. plasminogen activator plasminogen activator /plas·min·o·gen ac·ti·va·tor/ (ak´ti-va?tor) see under activator. plasminogen activator n. See urokinase. receptor, a key receptor responsible for solid tumor growth and metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases 1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to . Angstrom recently announced a strategic alliance with Diatide Inc. based in Londonderry, N.H. to develop diagnostic and therapeutic radiopharmaceuticals for cancer. Angstrom is also currently in discussions with several major pharmaceutical companies for the outlicensing of its anti-metastatic drug, A6. When used in this report, the word "will", and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected, anticipated, or implied. Factors that could cause or contribute to such differences include an inability to duplicate in the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the company's potential products and the risk factors set forth from time to time in a prospectus pursuant to which Angstrom is offering securities. The company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion